Good morning, all. A quiet week of deal news from Medical Devices and Biotech. Here are the top headlines that I found. It was a busy week of earnings reports though, so hopefully more acquisition and fund raising news next week. Let me know if I have missed anything.
🔔 Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200, establishing it as a challenger to Travere Therapeutics in a rare kidney disease.
🔔 Deerfield Management has unveiled the third instalment of its healthcare innovations fund, earmarking more than $600 million for promising therapeutics and technologies.
🔔 The United Kingdom aims to boost its life sciences profile as Aviva Capital Partners and Socius unveiled plans for a £1 billion ($1.3 billion) cancer research and manufacturing hub on the outskirts of London on Thursday.
🔔 Concentra acquires struggling small-molecule biotech Kronos Bio for 57 cents per share.
🔔 Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making the outlay, around half of which is upfront, to buy Regulus Therapeutics for a rare renal disease drug that is set to enter phase 3 in the third quarter.
🔔 HistoSonics is shopping for a potential buyer of its approach to destroying liver tumors with focused sound waves, according to the Financial Times. That includes early takeover discussions with major medtechs including Medtronic, GE HealthCare and Johnson & Johnson, at valuations possibly north of $2.5 billion, the report said.
===============
Newton Colmore is a specialist search firm and we connect exceptional engineering and scientific talent with impactful companies, globally.
#medicaldevices #healthcare #biotechnology #science #therapeutics